{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:29:26Z","timestamp":1793532566039,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1124\/jpet.123.002002","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T13:20:23Z","timestamp":1726492823000},"page":"346-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors"],"prefix":"10.1016","volume":"391","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4631-0085","authenticated-orcid":false,"given":"Sneha","family":"Rathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Mladek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Dragojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Burgenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Talele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina K.","family":"Bakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.002002_bib1","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399411001888","article-title":"Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain","volume":"13","author":"Agarwal","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"10.1124\/jpet.123.002002_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/jpet.123.002002_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01062139","article-title":"Testing for the equality of area under the curves when using destructive measurement techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.123.002002_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11060-017-2427-7","article-title":"GBM radiosensitizers: dead in the water \u2026 or just the beginning?","volume":"134","author":"Bindra","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1124\/jpet.123.002002_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph1416s52","article-title":"Establishment, maintenance, and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery","volume":"52","author":"Carlson","year":"2011","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1124\/jpet.123.002002_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5414\/CPP39093","article-title":"A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans","volume":"39","author":"Chiou","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/jpet.123.002002_bib7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/jpet.123.002002_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002002_bib9","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2019.37.15_suppl.3007","article-title":"First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors","volume":"37","author":"De Bono","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.123.002002_bib10","article-title":"ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost","volume":"2","author":"de Gooijer","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1124\/jpet.123.002002_bib11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/mp300570z","article-title":"Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states","volume":"10","author":"Deo","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.123.002002_bib12","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1124\/dmd.111.038778","article-title":"Species independence in brain tissue binding using brain homogenates","volume":"39","author":"Di","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.123.002002_bib13","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1124\/jpet.123.002002_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244.012","article-title":"A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)","volume":"30","author":"Dillon","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1124\/jpet.123.002002_bib15","first-page":"16","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1124\/jpet.123.002002_bib16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1172\/JCI114279","article-title":"Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation","volume":"84","author":"Dubey","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.123.002002_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"40","author":"Fokas","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/jpet.123.002002_bib18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4155\/fmc.15.33","article-title":"Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer","volume":"7","author":"Foote","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1124\/jpet.123.002002_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13014-018-1020-3","article-title":"ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration","volume":"13","author":"Fr\u00f2sina","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1124\/jpet.123.002002_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1293\/tox.2020-0007","article-title":"Patient-derived xenograft (PDX) models: characteristics and points to consider for the process of establishment","volume":"33","author":"Fujii","year":"2020","journal-title":"J Toxicol Pathol"},{"key":"10.1124\/jpet.123.002002_bib21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.123.002002_bib22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1124\/jpet.123.002002_bib23","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.123.002002_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.123.002002_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-022-04436-0","article-title":"Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice","volume":"89","author":"Kiesel","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.123.002002_bib26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.123.002002_bib27","doi-asserted-by":"crossref","first-page":"89707","DOI":"10.18632\/oncotarget.21111","article-title":"BMI1 reduces ATR activation and signalling caused by hydroxyurea","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.123.002002_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1124\/jpet.123.002002_bib29","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.002002_bib30","article-title":"The promise of DNA damage response inhibitors for the treatment of glioblastoma","volume":"3","author":"Majd","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1124\/jpet.123.002002_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1210\/edrv-10-3-232","article-title":"The free hormone hypothesis: a physiologically based mathematical model","volume":"10","author":"Mendel","year":"1989","journal-title":"Endocr Rev"},{"key":"10.1124\/jpet.123.002002_bib32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.123.002002_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-012-0979-0","article-title":"ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells","volume":"110","author":"Nadkarni","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1124\/jpet.123.002002_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1124\/jpet.123.002002_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ijms22010351","article-title":"Molecular mechanisms of treatment resistance in glioblastoma","volume":"22","author":"Ou","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.123.002002_bib36","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.1523\/JNEUROSCI.1907-09.2009","article-title":"Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord","volume":"29","author":"Overland","year":"2009","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.123.002002_bib37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI102664","article-title":"Thyroid function in nephrosis","volume":"31","author":"Recant","year":"1952","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.123.002002_bib38","article-title":"Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents","volume":"119","author":"Richner","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1124\/jpet.123.002002_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.123.002002_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1124\/jpet.123.002002_bib41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1535-7163.MCT-06-0691","article-title":"Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel","volume":"6","author":"Sarkaria","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.123.002002_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.123.002002_bib43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/path.6032","article-title":"Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition","volume":"259","author":"Sundararajan","year":"2023","journal-title":"J Pathol"},{"key":"10.1124\/jpet.123.002002_bib44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.121.000845","article-title":"Brain distribution of berzosertib: an ataxia telangiectasia and Rad3-related protein inhibitor for the treatment of glioblastoma","volume":"379","author":"Talele","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002002_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphar.2015.00181","article-title":"What is synergy? The Saariselk\u00e4 agreement revisited","volume":"6","author":"Tang","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.123.002002_bib46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-1110(75)90002-0","article-title":"Hydroxyurea","volume":"32","author":"Timson","year":"1975","journal-title":"Mutat Res"},{"key":"10.1124\/jpet.123.002002_bib47","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1021\/acs.molpharmaceut.0c00178","article-title":"Comparison of absolute protein abundances of transporters and receptors among blood-brain barriers at different cerebral regions and the blood-spinal cord barrier in humans and rats","volume":"17","author":"Uchida","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.123.002002_bib48","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/neuonc\/noaa149","article-title":"Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review","volume":"22","author":"Vogelbaum","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1124\/jpet.123.002002_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.123.002002_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2006.11.004","article-title":"Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis","volume":"82","author":"Weppler","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1124\/jpet.123.002002_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1124\/jpet.123.002002_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3153","article-title":"A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors","volume":"39","author":"Yap","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.123.002002_bib53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jps.2600820718","article-title":"Estimation of variance for AUC in animal studies","volume":"82","author":"Yuan","year":"1993","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.123.002002_bib54","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s11095-023-03574-1","article-title":"How much is enough? Impact of efflux transporters on drug delivery leading to efficacy in the treatment of brain tumors","volume":"40","author":"Zhang","year":"2023","journal-title":"Pharm Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652417797X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652417797X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.002002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:36:51Z","timestamp":1739961411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652417797X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S002235652417797X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.002002","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.002002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}